6533b822fe1ef96bd127d765

RESEARCH PRODUCT

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma

Vincenzo DenaroMichele IulianiSonia SimonettiAntonio RussoAlberto Di MartinoFrancesco PantanoGiuseppe ToniniDaniele SantiniGiulia RibelliBruno Vincenzi

subject

renal cell carcinomaCabozantinibQH301-705.5Biologyurologic and male genital diseasesGeneral Biochemistry Genetics and Molecular BiologyArticleGreen fluorescent proteinchemistry.chemical_compoundCabozantinib; Osteoblasts; Renal cell carcinomaRenal cell carcinomacabozantinibmedicineBiology (General)Antitumor activityGeneral Immunology and MicrobiologyCell growthOsteoblastosteoblastsmedicine.diseasefemale genital diseases and pregnancy complicationsInhibitory potencychemistryCancer researchMolecular ProfileGeneral Agricultural and Biological Sciences

description

Background: The presence of bone metastases in renal cell carcinoma (RCC) negatively affects patients’ survival. Data from clinical trials has highlighted a significant benefit of cabozantinib in bone metastatic RCC patients. Here, we evaluated the antitumor effect of cabozantinib in coculture models of renal cell carcinoma (RCC) and osteoblasts (OBs) to investigate whether and how its antiproliferative activity is influenced by OBs. Methods: Bone/RCC models were generated, coculturing green fluorescent protein (GFP)-tagged Caki-1 and 786-O cells with human primary OBs in a “cell–cell contact” system. RCC proliferation and the OB molecular profile were evaluated after the cabozantinib treatment. Results: The Caki-1 cell proliferation increased in the presence of OBs (p &lt

yearjournalcountryeditionlanguage
2021-08-16Biology
10.3390/biology10080781http://dx.doi.org/10.3390/biology10080781